Helen Adams
Medical · New York, NYNPI 1588844815
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,075 of the $86,665 with a category attached, or 69.3%. 12 manufacturers reported payments, led by AbbVie at 52.8% of the total. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $288.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Gilead$26K
- Madrigal Pharmaceuticals$12K
- Ipsen Biopharmaceuticals, Inc$894
- Intercept Pharmaceuticals, Inc.$755
- AstraZeneca$261
- plus $692 from 6 others
What the payments were for
- Consulting fees$3,2004%
- Speaking & faculty fees$60,07569%
- Travel & lodging$12,82615%
- Food & beverage$10,56412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 112 | $45,788 |
| Gilead | 131 | $26,461 |
| Madrigal Pharmaceuticals | 35 | $11,812 |
| Ipsen Biopharmaceuticals, Inc | 6 | $894 |
| Intercept Pharmaceuticals, Inc. | 5 | $755 |
| AstraZeneca(2 entities) | 3 | $261 |
| GSK | 1 | $250 |
| Orphalan Inc | 2 | $141 |
| Alcresta Therapeutics, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $105 |
| Eiger Biopharmaceuticals, Inc. | 1 | $55 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,665 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 15 | $356,176 |
| VemlidyTenofovir Alafenamide | 73 | $107,197 |
| XifaxanRifaximin | 29 | $91,372 |
| Entecavir | 65 | $13,303 |
| Ursodiol | 112 | $10,033 |
| Tenofovir Disoproxil Fumarate | 11 | $1,455 |
| Mesalamine | 12 | $1,363 |
| Lactulose | 31 | $1,157 |
| Nadolol | 19 | $859 |
| Famotidine | 74 | $681 |
| Omeprazole | 44 | $344 |
| Pantoprazole Sodium | 42 | $307 |
| Azathioprine | 14 | $227 |
| Spironolactone | 24 | $180 |
| Furosemide | 20 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $26,461 | $463,37388 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $105 | $91,37229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in New York
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Maureen ThyneNew York$109K
- Hailey BrickmanNew York$82K
- Maria BaldoNew York$40K
- Michael QuerijeroNew York$32K
- Meiting LiangNew York$25K
- Karina SodenNew York$23K
- Noah KiefferNew York$19K
- Monica HarilallNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.